Nebenwirkungen · Nulojix
NULOJIX 250 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 13
HOS-213636 · Präparat HOS-155150
During the long-term extension period in newly transplanted patient trials, serious infections occurred in 30.3% and 23.5% of patients in the belatacept MI and LI groups, respectively, and in 27.2% of patients in the ciclosporin group in Study 1; and in 35.6% and 38.1% of patients in the belatacept MI and LI groups, respectively, and in 37.9% of patients in the ciclosporin group in Study 2. There was one case of PML reported (Study 1) in the ciclosporin group at 82 months post-transplant (more than 56 days after discontinuing therapy).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-20T13:32:00Z · SHA-256 699ad0365be092c03037bcab8ddbe9297f4376d0afffb7e9c952313b11ba0943 · Passage aa6eaf51bbc7be37df8e41dfed6a1a54b48a366303868aa9ae28d3436eaf7a9f · Zeichen 17569–18110 im Abschnitt